TDA6 Antibody

What is TDA6 protein and why is it significant in research?

TDA6 (Q06466) is a protein found in Saccharomyces cerevisiae (strain ATCC 204508 / S288c), commonly known as baker's yeast. While the specific function of TDA6 remains under investigation, studying this protein contributes to our understanding of yeast cellular processes. Antibodies against TDA6 are valuable tools for detecting and quantifying this protein in experimental settings using techniques such as Western blotting and ELISA . The significance lies in its potential role in fundamental cellular mechanisms that may be conserved across species.

What are the validated applications for TDA6 Antibody?

Based on current research protocols and manufacturer specifications, TDA6 Antibody has been validated for the following applications:

The antibody has demonstrated specific binding to recombinant TDA6 protein with an antibody titer >1:64,000 confirmed by ELISA, and antibody purity >90% confirmed by SDS-PAGE . When using this antibody, researchers should expect positive Western blot results with the immunogen protein, though this may not apply when using synthetic peptides as targets .

What is the recommended protocol for using TDA6 Antibody in Western blotting?

For optimal Western blot results with TDA6 Antibody, follow this methodological approach:

• Sample preparation: Extract total protein from yeast cells using standard protocols (glass bead lysis in buffer containing protease inhibitors).

• Protein separation: Load 20-50 μg of protein per lane on 10-12% SDS-PAGE gel.

• Transfer: Transfer proteins to PVDF or nitrocellulose membrane using standard transfer conditions.

• Blocking: Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary antibody: Dilute TDA6 Antibody 1:1000 in blocking buffer and incubate overnight at 4°C.

• Washing: Wash membrane 3 times with TBST, 5 minutes each.

• Secondary antibody: Incubate with HRP-conjugated anti-rabbit IgG (1:5000) for 1 hour at room temperature.

• Detection: Visualize using enhanced chemiluminescence substrate.

For positive control, include recombinant TDA6 protein alongside your experimental samples . This protocol mirrors approaches used for other yeast antibodies and has been validated for specificity.

How can TDA6 Antibody be utilized in immunoprecipitation experiments?

While immunoprecipitation (IP) is not explicitly listed among the validated applications for TDA6 Antibody, researchers can adapt the antibody for IP following these methodological guidelines:

• Cell lysis: Lyse yeast cells in a non-denaturing lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease inhibitors).

• Pre-clearing: Pre-clear lysate with Protein A/G beads for 1 hour at 4°C.

• Antibody binding: Incubate pre-cleared lysate with 2-5 μg of TDA6 Antibody overnight at 4°C.

• Immunoprecipitation: Add Protein A/G beads and incubate for 2-4 hours at 4°C.

• Washing: Wash beads 4-5 times with lysis buffer.

• Elution: Elute bound proteins by boiling in SDS sample buffer.

• Analysis: Analyze by Western blotting using a different antibody (if available) or mass spectrometry.

What controls should be included when using TDA6 Antibody in immunofluorescence studies?

For immunofluorescence experiments using TDA6 Antibody, include these essential controls:

• Negative control: Samples from TDA6 knockout yeast strains or wild-type cells with primary antibody omitted.

• Isotype control: Use rabbit IgG at the same concentration as TDA6 Antibody to assess non-specific binding.

• Peptide competition: Pre-incubate TDA6 Antibody with excess recombinant TDA6 protein before staining to confirm specificity.

• Positive control: Use a strain with known high expression of TDA6 or a strain overexpressing tagged TDA6.

• Secondary antibody control: Perform staining with secondary antibody alone to detect non-specific binding.

These controls are critical for establishing the specificity of immunofluorescence signals, especially since immunofluorescence is not explicitly listed among validated applications for this antibody . The methodological approach mirrors that used for validating antibodies against other yeast proteins, as seen in comprehensive antibody validation studies.

How can TDA6 Antibody be used in combination with other antibodies for multi-protein localization studies?

For multi-protein localization studies, researchers can employ TDA6 Antibody alongside antibodies targeting other yeast proteins using these methodological approaches:

• Sequential staining: For co-localization with another rabbit antibody:

  • First perform complete staining with TDA6 Antibody using a directly conjugated secondary antibody

  • Block with excess rabbit IgG

  • Stain with the second primary antibody followed by a differently labeled secondary antibody

• Simultaneous staining: For co-staining with antibodies from different host species:

  • Incubate samples with a mixture of TDA6 Antibody and antibodies raised in different species (mouse, goat, etc.)

  • Detect using species-specific secondary antibodies with different fluorophores

• Proximity ligation assay (PLA): To detect potential protein-protein interactions:

  • Incubate fixed cells with TDA6 Antibody and a mouse antibody against a suspected interacting protein

  • Follow PLA protocol using anti-rabbit and anti-mouse PLA probes

  • Proximity signals will indicate if proteins are within 40 nm of each other

When designing these experiments, consider potential cross-reactivity between antibodies and ensure that fixation conditions are compatible with all antibodies used . This approach parallels methods used in antibody-based protein interaction studies for other cellular systems.

What are the considerations for using TDA6 Antibody in chromatin immunoprecipitation (ChIP) experiments?

While ChIP is not a validated application for TDA6 Antibody, researchers investigating potential DNA-binding properties of TDA6 might consider adapting the antibody for ChIP with these methodological considerations:

• Crosslinking optimization: Test different formaldehyde concentrations (0.75-1.5%) and incubation times (10-20 minutes) to preserve protein-DNA interactions without overfixing.

• Sonication parameters: Optimize sonication conditions to achieve chromatin fragments of 200-500 bp, typically requiring:

  • 10-15 cycles of 30 seconds ON/30 seconds OFF

  • Medium power setting

  • Verification of fragment size by agarose gel electrophoresis

• Antibody amount optimization: Test different amounts of TDA6 Antibody (2-10 μg per ChIP reaction) to determine optimal signal-to-noise ratio.

• Controls:

  • Input chromatin (non-immunoprecipitated)

  • IgG control (non-specific rabbit IgG)

  • Positive control (antibody against a known DNA-binding protein)

  • Negative control regions for qPCR

• Validation strategies:

  • Independent ChIP with a different antibody or tagged version of TDA6

  • Sequential ChIP (re-ChIP) if investigating co-occupancy with other proteins

Because the nuclear localization and DNA-binding properties of TDA6 have not been extensively characterized, these experiments would be considered exploratory . This methodological approach is based on established ChIP protocols adapted for novel targets.

How can deep learning and topological data analysis be integrated with TDA6 Antibody studies?

Integrating advanced computational approaches like deep learning and topological data analysis (TDA) with TDA6 Antibody research can provide novel insights through these methodological strategies:

• Image analysis pipeline:

  • Train a U-Net with an EfficientNet encoder (similar to EUNet) to detect TDA6-positive structures in immunofluorescence images

  • Apply data augmentation techniques to expand limited training datasets

  • Use transfer learning from pre-trained networks to improve performance with limited data

• Topological feature extraction:

  • Apply TDA to characterize the spatial distribution patterns of TDA6 in different cellular conditions

  • Generate persistence diagrams (PD) and Betti curves to quantify topological features

  • Integrate with uniform manifold approximation and projection (UMAP) for dimensionality reduction

• Multi-protein interaction network analysis:

  • Combine TDA6 immunoprecipitation data with proteomics

  • Apply hierarchical density-based spatial clustering (HDBSCAN) to identify protein complexes

  • Use TwoNN approach to study the intrinsic dimensionality of protein interaction networks

This integration allows researchers to move beyond visual inspection to quantitative characterization of TDA6 distribution and interaction patterns . Similar computational approaches have been successfully applied to antibody studies in digital pathology, demonstrating their potential value for yeast protein research.

What strategies can resolve non-specific binding issues when using TDA6 Antibody?

When encountering non-specific binding with TDA6 Antibody, implement these methodological solutions:

• Optimization of blocking conditions:

  • Test different blocking agents (5% BSA, 5% normal serum, commercial blocking buffers)

  • Increase blocking time from 1 hour to overnight at 4°C

  • Add 0.1-0.5% Triton X-100 to blocking buffer to reduce hydrophobic interactions

• Antibody dilution optimization:

  • Perform a dilution series (1:500, 1:1000, 1:2000, 1:5000)

  • Extend primary antibody incubation to overnight at 4°C with higher dilutions

  • Pre-absorb antibody with yeast extract from a TDA6 knockout strain

• Buffer optimization:

  • Increase salt concentration in wash buffers (150-500 mM NaCl)

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Include 5-10 mM glycine in antibody dilution buffer to reduce non-specific interactions

• Cross-adsorption protocol:

  • Incubate diluted antibody with yeast extract from a TDA6 knockout strain

  • Centrifuge at 12,000g for 10 minutes to remove antibody-antigen complexes

  • Use the supernatant for immunodetection

These approaches should systematically isolate and eliminate sources of non-specific binding . Similar strategies have been successfully implemented for improving specificity of other yeast antibodies in various applications.

How should researchers troubleshoot weak or absent signals when using TDA6 Antibody?

When faced with weak or absent signals using TDA6 Antibody, follow this systematic troubleshooting approach:

• Protein expression verification:

  • Confirm TDA6 expression in your samples using RT-PCR

  • Consider conditions that might upregulate TDA6 expression

  • Verify protein extraction efficiency using total protein stains

• Epitope accessibility improvements:

  • Test different fixation methods (formaldehyde, methanol, acetone)

  • Include an antigen retrieval step (heat-induced or enzymatic)

  • For Western blotting, ensure complete protein denaturation and reduction

• Signal amplification methods:

  • Employ a biotin-streptavidin amplification system

  • Use tyramide signal amplification (TSA)

  • Try a more sensitive detection system (enhanced chemiluminescence plus)

• Technical optimizations:

  • Reduce washing stringency (shorter washes, gentler agitation)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading for Western blots (50-100 μg)

  • For immunofluorescence, use a higher NA objective and optimize exposure settings

• Antibody concentration:

  • Try higher concentrations of primary antibody (1:250-1:500)

  • Ensure secondary antibody compatibility and freshness

This methodical approach addresses the most common causes of signal issues when working with yeast antibodies . Each modification should be tested individually to identify the specific limitation in your experimental system.

What are the storage and handling recommendations to maintain TDA6 Antibody efficacy?

To maintain optimal TDA6 Antibody performance over time, follow these evidence-based storage and handling guidelines:

• Storage conditions:

  • Store antibody at -20°C or -80°C for long-term storage as recommended by manufacturers

  • Avoid repeated freeze-thaw cycles by preparing single-use aliquots (10-20 μl)

  • For working solutions, store at 4°C with preservative (0.03% Proclin 300 or 0.02% sodium azide)

• Handling precautions:

  • Avoid contamination by using sterile pipette tips and tubes

  • Centrifuge vials briefly before opening to collect liquid at the bottom

  • Never vortex antibody solutions; mix by gentle inversion or flicking

• Stability assessment:

  • Include a positive control in each experiment to monitor antibody performance over time

  • Document lot numbers and prepare reference samples for comparison

  • If efficacy decreases, test a titration series to determine if higher concentrations can compensate

• Transportation considerations:

  • Ship on blue ice or dry ice depending on duration

  • Monitor temperature during transport if possible

  • Allow antibody to equilibrate to room temperature before opening after shipping

• Reconstitution of lyophilized antibody (if applicable):

  • Use sterile ddH₂O or buffer recommended by manufacturer

  • Allow complete dissolution without vigorous mixing

  • Equilibrate to room temperature before opening to prevent condensation

These practices are based on standard antibody handling protocols and specific manufacturer recommendations for TDA6 Antibody . Proper storage and handling significantly extend antibody shelf-life and maintain consistent experimental results.

How might TDA6 Antibody be applied in large-scale proteomic studies?

TDA6 Antibody could contribute to large-scale proteomic studies through these methodological approaches:

• Antibody-based proteomics:

  • Integration into antibody microarrays for high-throughput screening

  • Use in reverse-phase protein arrays to analyze TDA6 across multiple samples

  • Application in multiplexed immunoassays using differentially labeled antibodies

• Affinity purification-mass spectrometry (AP-MS):

  • Immobilize TDA6 Antibody on beads for pulldown of TDA6 and interacting partners

  • Combine with SILAC or TMT labeling for quantitative interaction proteomics

  • Implement crosslinking mass spectrometry to capture transient interactions

• Spatial proteomics applications:

  • Use in imaging mass cytometry for multiparameter spatial analysis

  • Apply for proximity labeling methods like BioID or APEX when coupled with fusion proteins

  • Integrate with automated high-content imaging systems for phenotypic analyses

• Integration with antibody engineering platforms:

  • Dataset generation for machine learning models that predict antibody-antigen interactions

  • Contribution to developing comprehensive yeast protein interactome maps

  • Validation of epitope prediction algorithms for yeast proteins

Similar approaches have been successfully implemented for antibody-based proteomics studies in other systems , and these methodologies could be adapted for TDA6 research in yeast.

What potential applications exist for TDA6 Antibody in synthetic biology and metabolic engineering of yeast?

In synthetic biology and metabolic engineering contexts, TDA6 Antibody could serve these potential applications:

• Protein production monitoring:

  • Quantify TDA6 fusion proteins in engineered expression systems

  • Monitor protein production stability over time and culture conditions

  • Validate protein localization in subcellular compartment engineering

• Biosensor development:

  • Create antibody-based biosensors for detecting TDA6-tagged proteins

  • Develop split-antibody complementation systems for protein-protein interaction studies

  • Engineer synthetic signaling pathways with TDA6 reporting components

• Metabolic pathway engineering:

  • Track expression of TDA6-tagged metabolic enzymes in optimized pathways

  • Monitor protein stability and degradation rates in different growth conditions

  • Quantify protein expression in mutant libraries for strain optimization

• Synthetic biology circuit validation:

  • Verify protein expression in synthetic genetic circuits

  • Quantify component expression levels in multi-protein assemblies

  • Analyze protein-protein interactions in synthetic pathway optimization

These applications build on established principles in antibody-based monitoring of engineered biological systems , adapted specifically for yeast engineering applications involving TDA6 protein or TDA6-tagged constructs.

How can TDA6 Antibody research benefit from recent advances in antibody engineering and therapeutic development?

TDA6 Antibody research can leverage recent advances in antibody engineering through these methodological implementations:

• Single-domain antibody development:

  • Generate camelid VHH (nanobodies) against TDA6 for improved penetration in intact cells

  • Develop single-domain antibodies with enhanced stability for harsh experimental conditions

  • Create multivalent VHH constructs for improved sensitivity, similar to approaches used for toxin detection

• Site-specific conjugation strategies:

  • Apply enzymatic conjugation methods (sortase, transglutaminase) for site-specific labeling

  • Implement click chemistry approaches for controlled antibody functionalization

  • Develop homogeneous antibody-fluorophore conjugates for quantitative imaging

• Humanization and expression optimization:

  • Apply computational design principles used in therapeutic antibody development to improve expression and stability

  • Implement humanization strategies based on canonical structure analysis and germline selection

  • Optimize complementarity-determining regions while maintaining specificity

• Machine learning integration:

  • Apply deep learning models trained on large antibody datasets to predict binding properties

  • Use computational approaches to design antibody variants with improved affinity

  • Implement AlphaSeq-like quantitative binding assays to generate training data for machine learning models